The preclinical stage company, Immugenia Inc., is engineering hematopoietic stem cells using proprietary specific promoters to express CAR in select immune cells, providing patients with a one-and-done treatment to fight hard-to-treat cancers and prevent relapses in hematological and solid tumors. By leveraging the synergistic activity of T and NK cells, Immugenia's next-generation CAR therapy aims to treat and prevent relapses in cancer patients.